Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

Vaccine. 2004 Aug 13;22(23-24):3182-6. doi: 10.1016/j.vaccine.2004.01.053.


Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase I, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intranasal
  • Adult
  • Animals
  • Antigen-Antibody Reactions
  • Chick Embryo
  • Cross Reactions
  • Dose-Response Relationship, Immunologic
  • Female
  • Humans
  • Male
  • Mice
  • Nasal Mucosa / immunology
  • Neutralization Tests
  • Parainfluenza Vaccines / adverse effects
  • Parainfluenza Vaccines / immunology
  • Parainfluenza Vaccines / therapeutic use*
  • Parainfluenza Virus 1, Human / immunology*
  • Respirovirus Infections / immunology*
  • Respirovirus Infections / prevention & control*
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology


  • Parainfluenza Vaccines
  • Vaccines, Attenuated